Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Ovarian Neoplasms

Free Subscription Articles published in Hum Pathol Retrieve available abstracts of 52 articles: HTML format

Single Articles

June 2020
1. ROTH LM, Cheng L
   Gonadoblastoma: origin and outcome.
   Hum Pathol. 2020;100:47-53.
   PubMed     Abstract available
   
   
   April 2020
2. TESSIER-CLOUTIER B, Cochrane DR, Karnezis AN, Colborne S, et al
   Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma.
   Hum Pathol. 2020 Apr 29. pii: S0046-8177(20)30047.
   PubMed     Abstract available
   
   
   February 2020
3. WIEDEMEYER K, Kobel M, Koelkebeck H, Xiao Z, et al
   High GLYPICAN-3 expression Characterizes a Biologically Distinct subset of ovarian clear cell carcinomas in Canadian patients: An Opportunity for targeted Therapy.
   Hum Pathol. 2020 Feb 1. pii: S0046-8177(20)30015.
   PubMed    
   
   
   October 2019
4. YOUNG RH, Frc, Path
   Ovarian tumors: a survey of selected advances of note during the LIFE of this journal.
   Hum Pathol. 2019 Oct 22. pii: S0046-8177(19)30167.
   PubMed     Abstract available
   
   
   August 2019
5. NOOR M, Chen A, Gonzalez RS
   Gynecologic proliferations of the appendix.
   Hum Pathol. 2019 Aug 17. pii: S0046-8177(19)30137.
   PubMed     Abstract available
   
   
   June 2019
6. ZHOUCHUNYANG X, Cochrane DR, Tessier-Coutier B, Leung S, et al
   Expression of L1 retrotransposon open reading frame protein 1 (L1ORF1p) in gynecologic cancers.
   Hum Pathol. 2019 Jun 17. pii: S0046-8177(19)30103.
   PubMed     Abstract available
   
   
   April 2019
7. TOMOHIRO M, Matsumoto T, Miura R, Oguri Y, et al
   Alterations in beta-catenin, microsatellite instability, and HNF-1beta levels are independently associated with ovarian endometriosis-associated tumorigenesis.
   Hum Pathol. 2019 Apr 22. pii: S0046-8177(19)30066.
   PubMed     Abstract available
   
   
   January 2019
8. SHEN W, Niu N, Lawson B, Qi L, et al
   GATA6: a new predictor for prognosis in ovarian Cancer.
   Hum Pathol. 2019 Jan 8. pii: S0046-8177(19)30003.
   PubMed     Abstract available
   
   
   November 2018
9. KATO N, Sato Y, Kamataki A, Fukase M, et al
   PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
   Hum Pathol. 2018 Nov 26. pii: S0046-8177(18)30464.
   PubMed     Abstract available
   
   
   
10. ISHIKAWA M, Nakayama K, Nakamura K, Ono R, et al
    High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Hum Pathol. 2018 Nov 15. pii: S0046-8177(18)30424.
    PubMed     Abstract available
    
    
    
11. BPH AY, Matsumoto T, Watanabe G, Tochimoto M, et al
    Immunophenotypic profile as predictor of prognosis in advanced ovarian carcinoma.
    Hum Pathol. 2018 Nov 15. pii: S0046-8177(18)30436.
    PubMed     Abstract available
    
    
    
12. BARRETA A, Sarian LO, Ferracini AC, Costa LBE, et al
    Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Hum Pathol. 2018 Nov 14. pii: S0046-8177(18)30427.
    PubMed     Abstract available
    
    
    
13. SEHOULI J, Braicu EI, Richter R, Denkert C, et al
    Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network.
    Hum Pathol. 2018 Nov 11. pii: S0046-8177(18)30417.
    PubMed     Abstract available
    
    
    
14. REIJNEN C, Kusters-Vandevelde HVN, Abbink K, Zusterzeel PLM, et al
    Quantification of Leydig cells and stromal hyperplasia in the postmenopausal ovary of women with endometrial carcinoma.
    Hum Pathol. 2018 Nov 11. pii: S0046-8177(18)30419.
    PubMed     Abstract available
    
    
    August 2018
15. PATEL V, Kipp B, Schoolmeester JK
    Corded and Hyalinized Mesonephric-like adenocarcinoma of the uterine Corpus: report of a case mimicking Endometrioid carcinoma.
    Hum Pathol. 2018 Aug 30. pii: S0046-8177(18)30334.
    PubMed     Abstract available
    
    
    
16. KARPATHIOU G, Matias-Guiu X, Mobarki M, Vermesch C, et al
    Ovarian neuroendocrine carcinoma of metastatic origin: clues for diagnosis.
    Hum Pathol. 2018 Aug 29. pii: S0046-8177(18)30330.
    PubMed     Abstract available
    
    
    
17. WANG J, Gao H, Liu G, Gu L, et al
    Tumor necrosis factor alpha-induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Hum Pathol. 2018 Aug 11. pii: S0046-8177(18)30301.
    PubMed     Abstract available
    
    
    June 2018
18. PRAT J, D'Angelo E, Espinosa I
    Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
    Hum Pathol. 2018 Jun 23. pii: S0046-8177(18)30230.
    PubMed     Abstract available
    
    
    
19. LI Z, Maeda D, Kudo-Asabe Y, Tamura D, et al
    MED12 is frequently mutated in ovarian and other adnexal Leiomyomas.
    Hum Pathol. 2018 Jun 23. pii: S0046-8177(18)30224.
    PubMed     Abstract available
    
    
    
20. LOPEZ LV, Bhattacharyya S, Carlsen ED, Bartlett D, et al
    NF2 and ATRX gene copy number losses on a case of ovarian ependymoma.
    Hum Pathol. 2018 Jun 23. pii: S0046-8177(18)30231.
    PubMed     Abstract available
    
    
    
21. PARK JK, Otsuka N, Tomaru U, Suzuki H, et al
    Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.
    Hum Pathol. 2018 Jun 21. pii: S0046-8177(18)30220.
    PubMed     Abstract available
    
    
    May 2018
22. ROUGEMONT AL, Tille JC
    Role of HNF1beta in the differential diagnosis from other germ cell tumors.
    Hum Pathol. 2018 May 10. pii: S0046-8177(18)30155.
    PubMed     Abstract available
    
    
    March 2018
23. HUI P, Gysler SM, Uduman M, Togun TA, et al
    MicroRNA Signatures Discriminate Between Uterine and Ovarian Serous Carcinomas.
    Hum Pathol. 2018 Mar 5. pii: S0046-8177(18)30070.
    PubMed     Abstract available
    
    
    
24. ROY M, Connor J, Al-Niaimi A, Rose SL, et al
    Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
    Hum Pathol. 2018;73:1-6.
    PubMed     Abstract available
    
    
    February 2018
25. ZHANG Y, Tao L, Yin C, Wang W, et al
    Ovarian microcystic stromal tumor with undetermined potential: Case study with molecular analysis and literature review.
    Hum Pathol. 2018 Feb 16. pii: S0046-8177(18)30053.
    PubMed     Abstract available
    
    
    
26. XING D, Banet N, Sharma R, Vang R, et al
    Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Hum Pathol. 2018;72:160-166.
    PubMed     Abstract available
    
    
    December 2017
27. OJALVO LS, Thompson ED, Wang TL, Meeker AK, et al
    Tumor-Associated Macrophages and the Tumor Immune Microenvironment of Primary and Recurrent Epithelial Ovarian Cancer (EOC).
    Hum Pathol. 2017 Dec 26. pii: S0046-8177(17)30478.
    PubMed     Abstract available
    
    
    November 2017
28. ESPINOSA I, De Leo A, D'Angelo E, Rosa-Rosa JM, et al
    Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Hum Pathol. 2017 Nov 10. pii: S0046-8177(17)30413.
    PubMed     Abstract available
    
    
    October 2017
29. ARTS FA, Keogh L, Smyth P, O'Toole S, et al
    miR-223 potentially targets SWI/SNF complex protein SMARCD1 in Atypical Proliferative Serous Tumor and High Grade Ovarian Serous Carcinoma.
    Hum Pathol. 2017 Oct 24. pii: S0046-8177(17)30377.
    PubMed     Abstract available
    
    
    
30. ESPINOSA I, D'Angelo E, Corominas M, Gonzalez A, et al
    Mixed Endometrial Carcinomas with a "Low-Grade Serous"-Like Component: a Clinicopathologic, Immunohistochemical, and Molecular Genetic Study.
    Hum Pathol. 2017 Oct 24. pii: S0046-8177(17)30385.
    PubMed     Abstract available
    
    
    September 2017
31. XING D, Rahmanto YS, Zeppernick F, Hannibal CG, et al
    Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma.
    Hum Pathol. 2017 Sep 2. pii: S0046-8177(17)30303.
    PubMed     Abstract available
    
    
    July 2017
32. RUSSO M, Broach J, Sheldon K, Houser KR, et al
    Clonal Evolution in Paired Endometrial Intraepithelial Neoplasia/Atypical Hyperplasia and Endometrioid Adenocarcinoma.
    Hum Pathol. 2017 Jul 13. pii: S0046-8177(17)30244.
    PubMed     Abstract available
    
    
    
33. SCHOOLMEESTER JK, Moyer AM, Goodenberger ML, Keeney GL, et al
    Pathologic Findings in Breast, Fallopian Tube and Ovary Specimens in non-BRCA Hereditary Breast and/or Ovarian Cancer Syndromes: A Study of 18 Patients with Deleterious Germline Mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH or CHEK2.
    Hum Pathol. 2017 Jul 11. pii: S0046-8177(17)30240.
    PubMed     Abstract available
    
    
    April 2017
34. ROTH LM, Lyu B, Cheng L
    Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms.
    Hum Pathol. 2017 Apr 23. pii: S0046-8177(17)30125.
    PubMed     Abstract available
    
    
    
35. AMAN M, Ohishi Y, Imamura H, Shinozaki T, et al
    Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
    Hum Pathol. 2017 Apr 21. pii: S0046-8177(17)30123.
    PubMed     Abstract available
    
    
    
36. WANG WC, Lai YC
    Mature cystic teratomas of the ovary-reply.
    Hum Pathol. 2017 Apr 20. pii: S0046-8177(17)30118.
    PubMed    
    
    
    
37. YAMASHITA Y
    Mature cystic teratomas of the ovary.
    Hum Pathol. 2017 Apr 18. pii: S0046-8177(17)30115.
    PubMed    
    
    
    
38. KIM WY, Shim SH, Jung HY, Dong M, et al
    The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Hum Pathol. 2017 Apr 17. pii: S0046-8177(17)30108.
    PubMed     Abstract available
    
    
    
39. TAUBE ET, Denkert C, Sehouli J, Unger U, et al
    Cytokeratin 5/6 expression, prognosis and association with ER-alpha in high-grade serous ovarian carcinoma.
    Hum Pathol. 2017 Apr 13. pii: S0046-8177(17)30105.
    PubMed     Abstract available
    
    
    
40. HAREL-DASSA K, Yedgar S, Trope CG, Davidson B, et al
    Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.
    Hum Pathol. 2017;62:115-121.
    PubMed     Abstract available
    
    
    February 2017
41. RAWISH KR, Desouki MM, Fadare O
    Atypical Mucinous Glandular Proliferations in Endometrial Samplings: Follow-Up and Other Clinicopathologic Findings In 41 cases.
    Hum Pathol. 2017 Feb 20. pii: S0046-8177(17)30048.
    PubMed     Abstract available
    
    
    
42. BRONER EC, Trope CG, Reich R, Davidson B, et al
    TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Hum Pathol. 2017;60:180-187.
    PubMed     Abstract available
    
    
    December 2016
43. ROSSI ED, Bizzarro T, Monterossi G, Inzani F, et al
    Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
    Hum Pathol. 2016 Dec 29. pii: S0046-8177(16)30357.
    PubMed     Abstract available
    
    
    November 2016
44. PELLETIER MP, Trinh VQ, Stephenson P, Mes-Masson AM, et al
    Microcystic, elongated and fragmented (MELF) pattern invasion is mainly associated with isolated tumor cell pattern metastases in FIGO grade I endometrioid endometrial cancer (EEC).
    Hum Pathol. 2016 Nov 15. pii: S0046-8177(16)30306.
    PubMed     Abstract available
    
    
    
45. WANG Y, Li M, Meng F, Lou G, et al
    HPIP Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with epithelial ovarian cancer.
    Hum Pathol. 2016 Nov 3. pii: S0046-8177(16)30286.
    PubMed     Abstract available
    
    
    October 2016
46. ZHANG C, Sung CJ, Quddus MR, Simon RA, et al
    Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: A clinicopathologic study of 238 cases.
    Hum Pathol. 2016 Oct 13. pii: S0046-8177(16)30245.
    PubMed     Abstract available
    
    
    September 2016
47. KATO N, Kusumi T, Kamataki A, Tsunoda R, et al
    DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: A potential association with androgenic effects.
    Hum Pathol. 2016 Sep 21. pii: S0046-8177(16)30213.
    PubMed     Abstract available
    
    
    
48. SCHOLZ B, Beckert M, Mordstein V, Hohmann N, et al
    Seromucinous borderline tumor of the testis-a case report.
    Hum Pathol. 2016 Sep 2. pii: S0046-8177(16)30206.
    PubMed     Abstract available
    
    
    June 2016
49. LIANG L, Jiang Y, Chen JS, Niu N, et al
    B7-H4 Expression in Ovarian Serous Carcinoma: A Study of 306 Cases.
    Hum Pathol. 2016 Jun 24. pii: S0046-8177(16)30129.
    PubMed     Abstract available
    
    
    
50. PASCUAL-GARCIA M, Bertolo C, Nieto JC, Serrat N, et al
    CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas.
    Hum Pathol. 2016 Jun 23. pii: S0046-8177(16)30124.
    PubMed     Abstract available
    
    
    
51. WANG WC, Lai YC
    Genetic analysis results of mature cystic teratomas of the ovary in Taiwan disagree with the previous origin theory of this tumor.
    Hum Pathol. 2016;52:128-35.
    PubMed     Abstract available
    
    
    March 2016
52. MANDATO VD, Aguzzoli L, Costagliola L, Abrate M, et al
    Diffuse large B-cell lymphoma occurring in an ovarian cystic teratoma: expanding the spectrum of large B-cell lymphoma associated with chronic inflammation.
    Hum Pathol. 2016 Mar 4. pii: S0046-8177(16)00073.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: